Cancer Drug Price Cuts Start Nov 9, Saving ₹3,502 Crore a Year
Cancer drug price cuts on 137 medicines take effect on 9 November 2026 as NPPA caps trade margins at 30%, saving patients about ₹3,502 crore a year.
Cancer drug price cuts on 137 medicines take effect on 9 November 2026 as NPPA caps trade margins at 30%, saving patients about ₹3,502 crore a year.
NPPA has released revised MRPs for 543 anti-cancer brands and packs under its 30% trade margin cap, effective 9 November, with generics and biosimilars cut by up to 93% while brands such as Avastin, Keytruda and nivolumab see no change.
NPPA has clarified that cancer-drug packs already in the market need not be recalled or relabelled when 30% trade-margin-capped prices for 137 drugs take effect on 9 November, provided retailers charge the revised MRP.
A Supreme Court bench asked why the drug pricing system appears to work for manufacturers, cited a hospital charging Rs 1.3 lakh for a cancer injection with an Rs 11,000 dealer price, and reserved its order on petitions over medicine pricing and trade margins.